Risdiplam is the only orally administered drug accredited with the treatment of SMA. It was FDA accepted in 2020 to be used in individuals two months of age and more mature, and it functions as an SMN2 gene splicing modifier leading to greater levels of SMN protein. Oral administration is https://albertoz964otx7.bloggadores.com/profile